Welcome reception

Welcome and introductions
Saad Usmani 

Session 1: Defining high-risk multiple myeloma
Chairs: Lawrence Boise & Leif Bergsagel

• Plasma cell identity escape as hallmark of high risk myeloma: Francesco Maura
• Defining functional high risk myeloma: Shaji Kumar
• Talk title TBC: Chng Wee Joo
• Talk title TBC: Martin Kaiser
• Talk title TBC: Faith Davies

Panel discussion

Break

Session 2: Circulating malignant plasma cell biology
Chairs: Paola Neri & TBC

• Talk title TBC: Karlo Perica
• Fragmentomic and genomic profiling of cell-free DNA to track tumour burden in multiple myeloma: Dory Abelman
• • Cell-free DNA as a non-invasive WGS surrogate in MM: Juan José Garcés

Panel discussion

 

Session 3: Extramedullary disease biology  

Chairs: Maximillian Merz & TBC

• Talk title TBC: Niels Weinhold
• Paramedullary/extramedullary myeloma dataset: Kylee Maclachlan
• Spatial and Single-Cell Characterization of Bone Marrow and Extramedullary Disease in Myeloma: Manoj Bhasin
• Talk title TBC: TBC
• Tackling extramedullary disease with immunotherapy: Darren Pan

Panel discussion

Lunch

Session 4: NSD2/MMSET disease subset         

Chairs: Marta Chesi & Faith Davies

• Targeting NSD2 and NSD2-dependent biology in t(4;14) MM: Benjamin Barwick
• Apoptotic dependencies in t(4;14) myeloma: Larry Boise
• The crossroads of t(4;14) breakpoints, NSD2 isoforms and patient outcome: Jonathan Keats
• Preclinical and translational data on a novel NSD2 inhibitor: Erin Flynt

Panel discussion           

Session 5: When standard risk isn’t: identifying functional high-risk myeloma

Chairs: Alfred Chung & TBC

• Rethinking Standard Risk: Biology of High-Risk t(11;14) MM: Linda Baughn
• Identifying tumor-reactive T cells: toward immune-based risk stratification in myeloma: Simone Minnie
• When does the immune system lose control? Host immune fitness as a determinant of high-risk myeloma: Erin Meermeier
• Talk title TBC: Marta Chesi
• OPTIMUM update: Martin Kaiser

Panel discussion

Break

 

Session 6: What we know about antigen loss

Chairs: Nizar Bahlis & TBC

• Talk title TBC: Holly Lee
• Talk title TBC: Ajay Nooka
• To B or not to B: How myeloma cell “identity” can predict therapy failure in RRMM: Ross Firestone
• Talk title TBC: TBC

Panel discussion

Session 6: New approaches for high risk – lab and clinic

Chairs: Jody Lipof and Alfred Chung

• In vivo CAR-T: Simon Harrison
• BMS 986453, a dual targeting BCMA x GPRC5D CAR-T for the treatment of RRMM: Doris Hansen
• Harnessing Ferroptosis for t(4;14) Multiple Myeloma Therapy: Mala Shanmugam
• Going to Great Lengths: Long Read Sequencing to Transform Myeloma Risk Stratification: Sarah Gooding

Panel discussion

Day 1 conclusions

Kylee Maclachlan

Faculty dinner

Welcome to Day 2
Kylee Maclachlan

Session 8: MAF/MAFB disease

Chairs: Francesco Maura & TBC

• • Should dysregulation of all MAF transcription factors be considered equal?: Jonathan Keats
• Talk title TBC: Leif Bergsagel
• Talk title TBC: Brian Walker

Panel discussion

Session 9: Designing studies in high-risk MM

Chairs: Shaji Kumar & Saad Usmani

• Overcoming “classical” HRMM by TCE-combinations: Currently available data and impact on study design: Marc Raab
• Talk title TBC: Sham Mailankody
• Timing of immunotherapy in randomized trials for high-risk myeloma: Binod Dhakal
• Talk title TBC: Tanya Wildes

Panel discussion

Break

Session 10: Treatment sequencing in high-risk MM

Chairs: Hamza Hassan & Tanya Wildes

• Talk title TBC: TBC
• Talk title TBC: Tom Martin
• Talk title TBC: TBC
• Talk title TBC: Ajay Nooka

Panel discussion

Session 11: The evolving role of MRD-guided treatment decisions

Chairs: Sham Mailankody & TBC

• Talk title TBC: Douglas Sborov
• MRD-guided and genomics-informed treatment adaptation in myeloma: Benjamin Diamond
• Talk title TBC: TBC
• Talk title TBC: TBC

Meeting conclusions and close

Saad Usmani

Lunch and adjourn